Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 5:49 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 564 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Conditioning Clear all
Completed Phase 2 Interventional Results available

Itacitinib, Tacrolimus, and Sirolimus for the Prevention of GVHD in Patients With Acute Leukemia, Myelodysplastic Syndrome, or Myelofibrosis Undergoing Reduced Intensity Conditioning Donor Stem Cell Transplantation

NCT04339101
View directory record Official record
Conditions
Acute Leukemia, Hematologic and Lymphocytic Disorder, Myelodysplastic Syndrome, Primary Myelofibrosis, Secondary Myelofibrosis
Interventions
Fludarabine, Itacitinib Adipate, Melphalan, Quality-of-Life Assessment, Questionnaire Administration, Sirolimus, Tacrolimus
Drug · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Oct 20, 2026, 5:49 AM EDT
Suspended Phase 1 Interventional

Intensity Modulated Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients With Relapsed Hematologic Cancers Undergoing a Second Donor Stem Cell Transplant

NCT02333162
View directory record Official record
Conditions
Previously Treated Myelodysplastic Syndrome, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid Leukemia, Recurrent Hematologic Malignancy
Interventions
Fludarabine Phosphate, Melphalan, Intensity-Modulated Radiation Therapy, Total Marrow Irradiation, Allogeneic Hematopoietic Stem Cell Transplantation, Peripheral Blood Stem Cell Transplantation, Allogeneic Bone Marrow Transplantation, Tacrolimus, Mycophenolate Mofetil, Laboratory Biomarker Analysis
Drug · Radiation · Procedure + 1 more
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2028
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Oct 20, 2026, 5:49 AM EDT
Completed Not applicable Interventional

Ischemic Conditioning in STEMI Patients

NCT03097419
View directory record Official record
Conditions
Cardiac Arrest
Interventions
Remote post-ischemic conditioning
Procedure
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 29, 2024 · Synced Oct 20, 2026, 5:49 AM EDT
Withdrawn Phase 1Phase 2 Interventional

Matched Related and Unrelated Donor Stem Cell Transplantation for Severe Combined Immune Deficiency (SCID): Busulfan-based Conditioning With h-ATG, Radiation, and Sirolimus

NCT04370795
View directory record Official record
Conditions
Severe Combined Immune Deficiency (SCID)
Interventions
Sirolimus, Busulfan, Horse -Anti-thymocyte, G-CSF, Total Body Irradiation (TBI)
Drug · Radiation
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
3 Years to 40 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 1, 2025 · Synced Oct 20, 2026, 5:49 AM EDT
Completed Phase 2 Interventional Results available

Netupitant and Palonosetron Hydrochloride in Preventing Chemotherapy Induced Nausea and Vomiting in Patients With Cancer Undergoing BEAM Conditioning Regimen Before Stem Cell Transplant

NCT03097588
View directory record Official record
Conditions
Malignant Neoplasm
Interventions
Netupitant, Palonosetron Hydrochloride, Questionnaire Administration
Drug · Other
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jul 12, 2021 · Synced Oct 20, 2026, 5:49 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Effects of Arousal and Stress in Anxiety

NCT00026559
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Shock Device, Auditory Startle Device
Device
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 50 Years
Enrollment
1,418 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001 – 2022
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 9, 2024 · Synced Oct 20, 2026, 5:49 AM EDT
Completed Phase 2 Interventional Results available

Relapse Prophylaxis With N-803 for AML and MDS Pts Following Allo HSCT

NCT02989844
View directory record Official record
Conditions
Acute Myelogenous Leukemia (AML), Myelodysplastic Syndrome (MDS)
Interventions
N-803
Drug
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 3, 2023 · Synced Oct 20, 2026, 5:49 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effectiveness of a Paleolithic Based Diet Compared to MyPlate Guidelines, With and Without Exercise, in Women.

NCT02380833
View directory record Official record
Conditions
Healthy
Interventions
MyPlate, MyPlate + Exercise, Paleolithic, Paleolithic + Exercise
Behavioral
Lead sponsor
Clemson University
Other
Eligibility
20 Years to 35 Years · Female only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Clemson, South Carolina
Source: ClinicalTrials.gov public record
Updated Nov 17, 2016 · Synced Oct 20, 2026, 5:49 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Ischemic Conditioning During Air tRansport Save penUmbral Tissue

NCT03481205
View directory record Official record
Conditions
Acute Stroke
Interventions
Ischemic conditioning device
Device
Lead sponsor
Enrique Leira
Other
Eligibility
18 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2026
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Nov 10, 2025 · Synced Oct 20, 2026, 5:49 AM EDT
Completed Phase 1 Interventional

Use of Busulfan as Conditioning Agent for a Second Stem Cell Transplant

NCT00092937
View directory record Official record
Conditions
Granulomatous Disease, Chronic
Interventions
Busulfan
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 20, 2026, 5:49 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Allogeneic SCT Of Pts With SCID And Other Primary Immunodeficiency Disorders

NCT00579137
View directory record Official record
Conditions
Severe Combined Immunodeficiency Disease, Severe Primary Immunodeficiency Disorder, Undefined T Cell Deficiency Disorder, Wiskott-Aldrick Syndrome
Interventions
Campath -1H, Fludarabine, Anti-CD45, Stem cell infusion
Biological · Drug · Procedure
Lead sponsor
Baylor College of Medicine
Other
Eligibility
Not listed
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 2, 2013 · Synced Oct 20, 2026, 5:49 AM EDT
Active, not recruiting Phase 1 Interventional Results available

Myeloablative Conditioning Orca-T & Allogeneic Donor-Derived CD19/CD22-CAR TCells in B-Cell ALL

NCT05507827
View directory record Official record
Conditions
Lymphoid Leukemia
Interventions
Allogeneic donor-derived T-cells transduced with bivalent lentiviral vector (CD19/CD22-BBz) chimeric antigen receptor (CAR), Treg CD34+HSPC (Orca-T)
Drug
Lead sponsor
Melody Smith
Other
Eligibility
18 Years to 65 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2045
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 20, 2026, 5:49 AM EDT
Terminated Phase 4 Interventional

Ischemic Conditioning (Delay Phenomenon) in Colorectal Surgery

NCT00887497
View directory record Official record
Conditions
Colon Rectal Resection
Interventions
Angioembolization
Procedure
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Sep 28, 2011 · Synced Oct 20, 2026, 5:49 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Operant H-reflex Down-conditioning of Rectus Femoris in Post-stroke Stiff Knee Gait

NCT05467774
View directory record Official record
Conditions
Training
Interventions
Operant RF H-reflex conditioning
Behavioral
Lead sponsor
University of Texas at Austin
Other
Eligibility
18 Years to 75 Years
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jul 16, 2024 · Synced Oct 20, 2026, 5:49 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Ischemic Conditioning Improves Walking Function Post Stroke

NCT04038697
View directory record Official record
Conditions
Stroke, Stroke, Ischemic, Stroke Hemorrhagic, Stroke, Cardiovascular
Interventions
Ischemic Conditioning, Ischemic Conditioning Sham, Treadmill Training
Procedure
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years to 85 Years
Enrollment
132 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2026
U.S. locations
2
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Oct 20, 2026, 5:49 AM EDT
Recruiting Not applicable Interventional

Remote Ischemic Conditioning and Spinal Reflex Modulation in Children With Cerebral Palsy

NCT07390760
View directory record Official record
Conditions
Children With Cerebral Palsy
Interventions
Remote Ischemic Condtioning (RIC), Sham conditioning, Balance training
Behavioral
Lead sponsor
East Carolina University
Other
Eligibility
8 Years to 17 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Greenville, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 24, 2026 · Synced Oct 20, 2026, 5:49 AM EDT
Completed Not applicable Interventional

Physiological Changes Induced Through MEP Conditioning in People With SCI

NCT04286191
View directory record Official record
Conditions
Spinal Cord Injuries, Neurological Injury, Paralysis, Spasticity, Muscle
Interventions
Operant Conditioning, Control Group
Combination Product
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Dec 9, 2025 · Synced Oct 20, 2026, 5:49 AM EDT
Completed Phase 2 Interventional Results available

Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in With High-Risk Hematologic Malignancies

NCT01760655
View directory record Official record
Conditions
Acute Myeloid Leukemia With FLT3/ITD Mutation, Acute Myeloid Leukemia With Gene Mutations, Acute Myeloid Leukemia With Inv(3) (q21.3;q26.2); GATA2, MECOM, Acute Myeloid Leukemia With t(6;9) (p23;q34.1); DEK-NUP214, Aplastic Anemia, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Chronic Myelomonocytic Leukemia, Follicular Lymphoma, Hodgkin Lymphoma, Myelodysplastic Syndrome, Myelofibrosis, Myeloid Leukemia, Non-Hodgkin Lymphoma, Plasma Cell Myeloma, Polycythemia Vera, Recurrent Adult Acute Myeloid Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia, Therapy-Related Acute Myeloid Leukemia
Interventions
Fludarabine phosphate, Busulfan, Total-Body Irradiation, Therapeutic Allogeneic Lymphocytes, Cyclophosphamide, Allogeneic Hematopoietic Stem Cell Transplantation, Peripheral Blood Stem Cell Transplantation, Tacrolimus, Mycophenolate Mofetil, Laboratory Biomarker Analysis
Drug · Radiation · Biological + 2 more
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Other
Eligibility
Not listed
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 30, 2025 · Synced Oct 20, 2026, 5:49 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Carfilzomib and Melphalan Before Stem Cell Transplant in Treating Patients With Multiple Myeloma

NCT01842308
View directory record Official record
Conditions
DS Stage I Plasma Cell Myeloma, DS Stage II Plasma Cell Myeloma, DS Stage III Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
Interventions
Autologous Bone Marrow Transplantation, Autologous Hematopoietic Stem Cell Transplantation, Carfilzomib, Laboratory Biomarker Analysis, Melphalan
Procedure · Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
2
States / cities
Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 1, 2020 · Synced Oct 20, 2026, 5:49 AM EDT
Completed Not applicable Interventional

Treatment for Teachers With Vocal Fatigue

NCT04486989
View directory record Official record
Conditions
Vocal Fatigue, Treatment
Interventions
Cardiovascular Conditioning Protocol, Voice Production Exercises
Behavioral · Other
Lead sponsor
East Tennessee State University
Other
Eligibility
21 Years to 60 Years · Female only
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Johnson City, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 18, 2023 · Synced Oct 20, 2026, 5:49 AM EDT
Completed Early Phase 1 Interventional Results available

Donor Stem Cell Transplantation for Congenital Immunodeficiencies

NCT00426517
View directory record Official record
Conditions
Inherited Immune Deficiencies
Interventions
Campath 1H, Busulfan, Horse Anti-human Thymocyte Globulin (h-ATG), Total Body Irradiation (TBI), Sirolimus or equivalent based on response
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
2 Years to 40 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 11, 2021 · Synced Oct 20, 2026, 5:49 AM EDT
Completed Phase 4 Interventional Results available

Conditioned Pharmacotherapeutic Effects in Hypertension

NCT02056626
View directory record Official record
Conditions
Hypertension
Interventions
carvedilol
Drug
Lead sponsor
University of Rochester
Other
Eligibility
18 Years to 80 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jul 9, 2019 · Synced Oct 20, 2026, 5:49 AM EDT
Completed Phase 2 Interventional Results available

Chemotherapy, Total-Body Irradiation, Rituximab, and Donor Stem Cell Transplant in Treating Patients With B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia

NCT00425802
View directory record Official record
Conditions
Leukemia, Lymphoma
Interventions
anti-thymocyte globulin, filgrastim, graft-versus-tumor induction therapy, rituximab, cyclophosphamide, cyclosporine, fludarabine phosphate, mycophenolate mofetil, nonmyeloablative allogeneic hematopoietic stem cell transplantation, total-body irradiation
Biological · Drug · Procedure + 1 more
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 70 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 31, 2017 · Synced Oct 20, 2026, 5:49 AM EDT
Completed Phase 1 Interventional

Alemtuzumab and Combination Chemotherapy Followed By Donor Lymphocytes in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer

NCT00104975
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
Interventions
alemtuzumab, therapeutic allogeneic lymphocytes, fludarabine phosphate, melphalan, tacrolimus, thiotepa, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
Yale University
Other
Eligibility
18 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Dec 15, 2016 · Synced Oct 20, 2026, 5:49 AM EDT